Skip to main content

Peer Review reports

From: A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

Original Submission
20 Dec 2021 Submitted Original manuscript
11 Jan 2022 Reviewed Reviewer Report
16 Mar 2022 Reviewed Reviewer Report
20 Apr 2022 Author responded Author comments - Farhad Shahi
27 Jun 2022 Reviewed Reviewer Report
13 Jul 2022 Author responded Author comments - Farhad Shahi
Resubmission - Version 2
20 Apr 2022 Submitted Manuscript version 2
19 Jul 2022 Editorially accepted
28 Jul 2022 Article published 10.1186/s40360-022-00599-x

You can find further information about peer review here.

Back to article page